Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan T Lei

Showing results (21-30 of 50) with videos related to

Pageof 5
Sort By:
Cell|June 25, 2024
Pan-cancer proteogenomics expands the landscape of therapeutic targetsSara R Savage, Xinpei Yi, Jonathan T Lei, et al.
Frontiers in Pharmacology|September 15, 2022
Epithelial immunomodulation by aerosolized Toll-like receptor agonists prevents allergic inflammation in airway mucosa in miceDavid L Goldblatt, Gabriella Valverde Ha, Shradha Wali, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 1, 2018
DPYSL3 modulates mitosis, migration, and epithelial-to-mesenchymal transition in claudin-low breast cancerRyoichi Matsunuma, Doug W Chan, Beom-Jun Kim, et al.
Cancer Research|April 18, 2023
Kinome Reprogramming Is a Targetable Vulnerability in ESR1 Fusion-Driven Breast CancerXuxu Gou, Beom-Jun Kim, Meenakshi Anurag, et al.
Nature Communications|May 22, 2025
Comprehensive evaluation of phosphoproteomic-based kinase activity inferenceSophia Müller-Dott, Eric J Jaehnig, Khoi Pham Munchic, et al.
Cancer Discovery|August 13, 2017
Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast CancerSvasti Haricharan, Nindo Punturi, Purba Singh, et al.
NPJ Breast Cancer|April 14, 2022
LINC00355 regulates p27<sup>KIP</sup> expression by binding to MENIN to induce proliferation in late-stage relapse breast cancerAbdallah M Eteleeb, Prasanth K Thunuguntla, Kyla Z Gelev, et al.
Science Translational Medicine|August 27, 2025
NF1-depleted ER<sup>+</sup> breast cancers are differentially sensitive to CDK4/6 inhibitorsZe-Yi Zheng, Anran Chen, Eric J Jaehnig, et al.
Cancer Research|October 29, 2021
Transcriptional Reprogramming Differentiates Active from Inactive ESR1 Fusions in Endocrine Therapy-Refractory Metastatic Breast CancerXuxu Gou, Meenakshi Anurag, Jonathan T Lei, et al.
Cancer Letters|May 30, 2026
NF1 loss in estrogen receptor-positive breast cancer induces osteoclast formation and immunosuppression to promote bone metastasisZifan Zhao, Ze-Yi Zheng, Jonathan T Lei, et al.
Pageof 5

Showing results (21-30 of 50) with videos related to

Sort By:
Pageof 5
Cell|June 25, 2024
Pan-cancer proteogenomics expands the landscape of therapeutic targetsSara R Savage, Xinpei Yi, Jonathan T Lei, et al.
Frontiers in Pharmacology|September 15, 2022
Epithelial immunomodulation by aerosolized Toll-like receptor agonists prevents allergic inflammation in airway mucosa in miceDavid L Goldblatt, Gabriella Valverde Ha, Shradha Wali, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 1, 2018
DPYSL3 modulates mitosis, migration, and epithelial-to-mesenchymal transition in claudin-low breast cancerRyoichi Matsunuma, Doug W Chan, Beom-Jun Kim, et al.
Cancer Research|April 18, 2023
Kinome Reprogramming Is a Targetable Vulnerability in ESR1 Fusion-Driven Breast CancerXuxu Gou, Beom-Jun Kim, Meenakshi Anurag, et al.
Nature Communications|May 22, 2025
Comprehensive evaluation of phosphoproteomic-based kinase activity inferenceSophia Müller-Dott, Eric J Jaehnig, Khoi Pham Munchic, et al.
Cancer Discovery|August 13, 2017
Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast CancerSvasti Haricharan, Nindo Punturi, Purba Singh, et al.
NPJ Breast Cancer|April 14, 2022
LINC00355 regulates p27<sup>KIP</sup> expression by binding to MENIN to induce proliferation in late-stage relapse breast cancerAbdallah M Eteleeb, Prasanth K Thunuguntla, Kyla Z Gelev, et al.
Science Translational Medicine|August 27, 2025
NF1-depleted ER<sup>+</sup> breast cancers are differentially sensitive to CDK4/6 inhibitorsZe-Yi Zheng, Anran Chen, Eric J Jaehnig, et al.
Cancer Research|October 29, 2021
Transcriptional Reprogramming Differentiates Active from Inactive ESR1 Fusions in Endocrine Therapy-Refractory Metastatic Breast CancerXuxu Gou, Meenakshi Anurag, Jonathan T Lei, et al.
Cancer Letters|May 30, 2026
NF1 loss in estrogen receptor-positive breast cancer induces osteoclast formation and immunosuppression to promote bone metastasisZifan Zhao, Ze-Yi Zheng, Jonathan T Lei, et al.
Pageof 5